title: Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
abstract: Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the "on" state increased more in the cabergoline group (p = 0.022). The side-effect was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.
authors.affiliation: Neurology Research and Education Center, St. Mary of the Plains Hospital, Lubbock, TX 79410, USA.
authors.forename: J T
authors.initials: JT
authors.lastname: Hutton
authors.forename: W C
authors.initials: WC
authors.lastname: Koller
authors.forename: J E
authors.initials: JE
authors.lastname: Ahlskog
authors.forename: R
authors.initials: R
authors.lastname: Pahwa
authors.forename: H I
authors.initials: HI
authors.lastname: Hurtig
authors.forename: M B
authors.initials: MB
authors.lastname: Stern
authors.forename: B C
authors.initials: BC
authors.lastname: Hiner
authors.forename: A
authors.initials: A
authors.lastname: Lieberman
authors.forename: R F
authors.initials: RF
authors.lastname: Pfeiffer
authors.forename: R L
authors.initials: RL
authors.lastname: Rodnitzky
authors.forename: C H
authors.initials: CH
authors.lastname: Waters
authors.forename: M D
authors.initials: MD
authors.lastname: Muenter
authors.forename: C H
authors.initials: CH
authors.lastname: Adler
authors.forename: J L
authors.initials: JL
authors.lastname: Morris
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004873:Ergolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009068:Movement; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010352:Patient Dropouts; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D010919:Placebos; D007980:Levodopa; D000077465:Cabergoline